Language: BG BG
← Back to results
Recruiting Phase 2 NCT05334316

Individualizing Corticosteroid Use in Pneumonia

Phase 2 – studying effectiveness and dosage
Conditions: Pneumonia

Sponsor: Mayo Clinic

trial.available_in: БГ
Overview
In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.
Who can participate
Inclusion Criteria: * Hospitalized adult (≥ 18 years) patients. * Community acquired pneumonia. Exclusion Criteria: * Contraindications or unwillingness to use corticosteroids by patient or provider. * History of adrenal insufficiency, septic shock, or another absolute indication for steroid use. * Suspected pulmonary vasculitis or other autoimmune pulmonary disorder. * Positive pregnancy test * Comfort care.
Interventions
Dexamethasone
DRUG
Locations 1
United States (1)
Mayo Clinic Rochester
Rochester , Minnesota
Technical details
Status
Recruiting
Phase
Phase 2
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
06.11.2024
Completion date
01.12.2026
Registry ID
NCT05334316
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.